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Abstract: CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which 
has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CD-
PEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale drug carrier system, the cyclodextrin po-
lymeric nanoparticle technology, referred to as “CDP”, has unique design features and capabilities. Specifically, 
CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and phar-
macokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological prop-
erties that enhance CPT pharmacodynamics and efficacy.  
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1. INTRODUCTION AND RATIONALE 
  Polymeric nanoparticles are promising drug carriers. Re-
search and development with drug-containing nanoparticles 
has shown that they can enhance aqueous solubility, prolong 
plasma half-life, and reduce systemic toxicity of che-
motherapeutic agents in vitro and in vivo [1,2]. However, 
more recent findings with polymeric nanoparticles have il-
lustrated their unique ability to introduce additional biologi-
cal advantages compared to other drug delivery technologies 
and approaches, such as liposomes, polymeric micelles, and 
prodrug conjugates. 
  Polymeric nanoparticles as drug carriers can be designed 
to have defined size and surface properties to favor drug 
deposition and retention in tumors by extravasation through 
disorganized leaky vasculature commonly found in tumors 
and inflamed tissues, described as the enhanced permeability 
and retention (EPR) effect [3,4]. The nanoparticle’s physical 
attributes can also be optimized to facilitate target tissue 
penetration and cellular uptake, thereby overcoming drug 
resistance by circumventing surface-pump mediated multi-
drug resistance (e.g. P-glycoprotein-mediated) mechanisms 
[2]. Furthermore, the physical and chemical properties can 
be designed to incorporate stealth properties and maintain 
physical integrity, which can shield drug molecules from 
rapid systemic clearance, degradation, and metabolism while 
in circulation, and prevent broad systemic drug dissemina-
tion and exposure in healthy tissues and organs. Finally, po-
lymeric nanoparticles can be engineered to incorporate drugs 
by covalent conjugation, which can provide control over 
drug-release kinetics that could have a significant impact on 
pharmacokinetics and a meaningful improvement in the 
drug’s pharmacodynamics and efficacy [2,5]. 
  CRLX101 is a polymeric nanoparticle pharmaceutical, 
developed with the proprietary cyclodextrin polymeric 
nanoparticle (CDP) technology [6,7]. It is comprised of 
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camptothecin (CPT) covalently conjugated to a linear, cy-
clodextrin-polyethylene glycol (CD-PEG) co-polymer, 
which self-assembles into nanoparticles (Fig. 1). Originally 
designed to address formulation challenges associated with 
CPT, a highly insoluble and labile small molecule, 
CRLX101 is a nanopharmaceutical that has proven to aug-
ment CPT efficacy by (a) facilitating target tissue localiza-
tion and retention, (b) increasing intracellular CPT deposi-
tion, (c) providing a sustained supply of active CPT, (d) 
maintaining intracellular CPT concentrations above thera-
peutic threshold, and (e) prolonging activity at the CPT tar-
get.  
1.1. Background 
  The 20S-isomer of CPT, a natural alkaloid isolated from 
the Chinese bush Camptotheca acuminata, was first identi-
fied in the National Cancer Institute (NCI) Anticancer Drug 
Screen as a promising cancer drug candidate with significant 
anti-tumor activity [8]. Its mechanism of action was later 
discovered to be potent inhibition of topoisomerase 1 (Topo 
1), which is an important and validated drug target for cancer 
therapy today. Topo 1 remains a highly attractive drug target 
because it is essential for basic cellular processes including 
DNA replication, recombination, and transcription, which 
are particularly up-regulated in rapidly dividing tumor cells 
[9]. A significant medicinal chemistry effort has been de-
voted to developing CPT analogs. There are currently two 
FDA-approved small molecule CPT analogs, topotecan   
(Hycamtin
®, GlaxoSmithKline) and irinotecan (Camptosar
®, 
Pfizer) [10]. While they are highly potent like CPT, both 
drugs exhibit sub-optimal pharmacokinetics and have sig-
nificant dose-limiting toxicities, including bone marrow sup-
pression and gastrointestinal disorders, respectively. As 
such, a better tolerated CPT molecule with enhanced efficacy 
and improved pharmacokinetics is a highly attractive cancer 
drug candidate that could have a significant and favorable 
clinical impact.  
  Given its original promise as an anti-tumor agent, CPT 
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ever, development of CPT as a drug molecule was halted 
because of its challenging physicochemical and pharmaceu-
tical properties. Firstly, CPT is highly water-insoluble (ap-
proximately 4 μg/mL) and is therefore not amenable to tradi-
tional pharmaceutical formulations. Secondly, the chemical 
structure of CPT includes an unstable lactone ring that is 
highly susceptible to spontaneous and reversible hydrolysis, 
which yields an inactive, but more water-soluble, carboxy-
late form that predominates at physiologic pH [11,12]. This 
inactive carboxylate form was also found to bind human 
serum albumin with 200-fold greater affinity than the active 
lactone form, therefore perpetuating its predominance in 
circulation upon parenteral administration [13]. Clinical 
formulation development effort at that time did not take into 
consideration the need to lock CPT in its active lactone form 
and to protect it from rapid hydrolysis upon administration. 
In fact, early clinical studies were conducted with the inac-
tive carboxylate form of CPT, which resulted in observations 
of significant drug-related toxicity but limited anti-tumor 
efficacy [14,15]. Any further advancement of CPT as a drug 
molecule will require formulations that release CPT in its 
active lactone form and maintain its biological activity by 
protecting it from hydrolysis. 
  From a mechanistic standpoint, a CPT therapeutic effect 
is anticipated to be maximized with improved pharmacoki-
netics; that is, lengthening its half-life and prolonging the 
bioavailability of the active lactone form. The rationale for 
an improved pharmacokinetic profile is two-fold. Firstly, 
CPT works by binding and stabilizing the transient DNA-
Topo 1 cleavable complex in a reversible manner. A short 
drug exposure or periodic drug withdrawal would likely al-
low cells to evade cell death. Sustained CPT exposure and 
prolonged inhibition of Topo 1 in cells undergoing active 
DNA synthesis is therefore expected to enhance CPT phar-
macodynamics and resulting efficacy [16]. Additionally, 
recent work at the NCI suggests that prolonged Topo 1 inhi-
bition can mediate a novel Topo 1-dependent hypoxia-
inducible factor 1 alpha (HIF-1) inhibition mechanism [17], 
another promising cancer drug target that has been the sub-
ject of intense research and screening efforts. In these stud-
ies, the researchers found that maximal HIF-1 inhibition 
and enhanced anti-tumor efficacy is best achieved with Topo 
1 inhibitors possessing extended pharmacokinetics, or with a 
daily low-dose dosing regimen to achieve a higher overall 
drug level over a longer period of time [18]. Together, these 
findings suggest that extending the pharmacokinetics of a 
Topo 1 inhibitor can prolong its on-target effect as well as 
augment its efficacy, potentially by activating a novel dual-
inhibition mechanism. 
1.2. Design of CRLX101 
  CRLX101 was designed to maximize CPT efficacy by 
addressing its formulation and pharmacokinetic hurdles. The 
chemical structure of CRLX101 is comprised of a linear co-
polymer backbone incorporating alternating repeat units of 
cyclodextrin (CD) and polyethylene glycol (PEG) blocks 
with intervening chemical linkers for CPT conjugation. One 
of the key design features of CDP is that the CD blocks form 
inclusion complexes with hydrophobic small molecule 
drugs, such as CPT, through both intra- and inter-molecular 
interactions. Such interactions between adjacent polymer 
strands are essential for catalyzing the self-assembly of sev-
eral CD-PEG polymer strands into highly reproducible 
nanoparticles with diameters between 30 and 40 nm [19] 
(Fig.  2). The resulting drug-containing nanoparticles have 
neutral surface charge and the PEG blocks impart improved 
solubility and stealth properties, which together enable safe 
systemic administration, minimize immunogenicity, and help 
evade phagocytic uptake by the reticuloendothelial system 
[20]. As a result, CRLX101 exhibits extended plasma stabil-
ity with prolonged circulation time, avoids rapid renal and 
systemic clearance, and accumulates in target tissues through 
the EPR effect.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Cryo-TEM of CRLX101. 
 
 
 
 
 
 
Fig. (1). Schematic diagram of CRLX101, a nanopharmceutical comprised of camptothecin conjugated to a linear, cyclodextrin-polyethylene 
glycol (CD-PEG) co-polymer and formulated into nanoparticles. 
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  Two other major design features of CDP as a drug carrier 
are the covalent linkage of CPT to the CD-PEG polymer and 
the physical integrity of the resulting self-assembled 
nanoparticles. To form CRLX101, CPT is derivatized at the 
20-OH position with the natural amino acid glycine to form 
an ester linkage for covalent attachment to CD-PEG. In vitro 
chemical characterization studies confirmed that this linker 
strategy successfully stabilizes the labile lactone ring of CPT 
in its closed, active form and prevents premature CPT inacti-
vation by pH-mediated ring opening upon systemic admini-
stration [6]. In addition, the physical integrity of CRLX101 
nanoparticles helps protect CPT from metabolic enzymes 
and premature hydrolysis. Consequently, only the active 
form of CPT is released in a controlled manner and over a 
sustained period of time. 
  Biocompatibility is another important design feature of 
CDP as a drug carrier technology. Preclinical animal study 
data demonstrated that the CD-PEG polymer, in the absence 
of conjugated drug, is well tolerated, eliciting no observable 
side effects or immune responses, despite dosing up to 240 
mg/kg in mice [6]. In CRLX101, the intra- and inter-
molecular interactions of CD-PEG polymer strands that cata-
lyze inclusion complex formation are lost upon CPT release, 
resulting in the disassembly of the nanoparticles into indi-
vidual polymer strands with hydrodynamic diameters of < 10 
nm. Such individual polymer strands are then sufficiently 
small and inert for clearance through the kidneys. In essence, 
CRLX101 has been designed as a CPT depot that disassem-
bles into biocompatible components that can be safely ex-
creted. These preclinical findings are consistent with our 
clinical experience of patients tolerating multiple cycles of 
CRLX101 therapy without experiencing any unusual or un-
expected non-drug related toxicity caused by the presence of 
CD-PEG co-polymer. 
  In summary, CDP is a highly versatile nanopharmaceuti-
cal technology that has several design features that address 
challenging pharmaceutical hurdles, as exemplified by its 
ability to substantially improve CPT solubility, maintain 
CPT biological activity upon administration, and control 
sustained CPT release, resulting in improved tolerability and 
enhanced efficacy in vivo [6,7]. 
2. PRECLINICAL CHARACTERIZATION OF 
CRLX101 
2.1. In Vitro Studies with CRLX101 
  To demonstrate the controlled and sustained CPT release 
from CDP, the drug release kinetics and mechanism of 
CRLX101 were studied extensively in vitro. Cleavage of the 
glycine linker was found to be mediated through both enzy-
matic and base-catalyzed hydrolysis of the ester bond, with 
observed half-lives of 59 hours and 41
1 hours in PBS and 
human plasma, respectively. While CPT release kinetics 
were observed to be relatively accelerated in plasma com-
pared to in PBS, the rate of drug release is slower than what 
                                                 
1 Originally published data indicated a half-life of 1.7 hours in human plasma (J. 
Cheng, K.T. Khin, G.S. Jensen, A. Liu & M.E. Davis Bioconjug Chem 14, 1007-17. 
(2003)). However, subsequent repeat analysis indicated a correct half-life of 41 hours 
in human plasma when the pH of the human plasma was adjusted to pH 7.4. Freshly 
reconstituted human plasma had a pH of approx. 9.5 prior to pH adjustment.  
is typically observed with polymeric pro-drugs with an ester 
linkage [21]. It should also be noted that the in vivo terminal 
half-life in rat, dog, and human are similar (34.6 hours, 28.8 
hours, and 31.8 hours, respectively), suggesting that hy-
drolysis of the glycine linker is not rate-limiting. In addition, 
the slow and sustained CPT release from CRLX101 also 
illustrates the physical shielding effects of CDP forming in-
tact nanoparticles, which protect the CPT payload and mini-
mize the enzymatic and chemical hydrolytic degradation.  
  Another key characteristic of CRLX101 as a nanophar-
maceutical is its ability to enter cells and release the CPT 
payload intracellularly. To assess the degree of cellular up-
take and intracellular localization, cell culture studies were 
conducted by incubating fluorescently-labeled CDP-based 
nanoparticles with exponentially growing PC-3 cells. In 
these studies, CDP nanoparticles were observed to co-
localize with the dye Lysotracker
®, indicating that cellular 
uptake of intact nanoparticles is mediated through an en-
dosomal pathway [7]. Since the release kinetics of CPT from 
CRLX101 are slow under acidic conditions typically found 
in these compartments, exposure of cancer cells to 
CRLX101 is therefore anticipated to accumulate in endoso-
mal and lysosomal compartments where CPT release is cata-
lyzed by intravesicular esterases. As a result, the active form 
of CPT is released in a slow, sustained manner from 
CRLX101 from an intracellular CPT depot. In a 48-hour 
cytotoxicity assay, the IC50 values for CRLX101 were ob-
served to be in the sub-micromolar range in a variety of hu-
man cancer cell lines (Table 1). The 2 to 10 times lower in 
vitro potency of CRLX101 compared CPT is consistent with 
the relatively slow CPT release from CRLX101 and with the 
data from the in vitro release studies described above.  
2.2. In Vivo Studies with CRLX101 
  A key goal for the design of CRLX101 is to enhance 
drug deposition in tumor tissues in order to increase efficacy 
and improve systemic tolerability. To assess localized drug 
concentrations in target tissues, the biodistribution of 
CRLX101 was evaluated in xenograft tumor-bearing mice 
(Table  2). In these studies, tumor samples were harvested 
from animals that were dosed with either CRLX101 or CPT, 
and assessed for localized drug concentrations. Remarkably, 
in tumor tissues harvested from animals treated with 
CRLX101 at its maximum tolerated dose (MTD), signifi-
cantly higher intratumoral concentrations of released CPT 
were measured at 24 and 48 hours post-administration, com-
pared to tumor CPT concentrations found in animals treated 
with CPT at its MTD. These observations strongly support 
CRLX101 as a nanopharmaceutical that can effectively en-
hance CPT localization and retention in tumor tissues by the 
EPR effect. Furthermore, a gradual increase in released CPT 
level in tumor relative to plasma was observed, increasing 
from approximately a 2.5:1 tumor-to-plasma ratio at 24 
hours to 21:1 at 48 hours post-administration. The observed 
increase in unconjugated CPT in tumor relative to plasma 
over a 24-hour period suggests that CPT may be released 
from CRLX101 localized within the tumor by the EPR ef-
fect, in addition to CPT distributing from plasma to tumor. 
These observations are in sharp contrast with the data ob-
served in animals administered with CPT (Table 2). CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical  Current Bioactive Compounds 2011, Vol. 7 No. 1    11 
  Drug concentrations in plasma and tumor were further 
assessed in tumor-bearing mice comparing CRLX101 with 
another Topo 1 inhibitor, irinotecan, a small-molecule pro-
drug of another active Topo 1 inhibitor, SN-38 [22]. In these 
experiments, drug levels were assessed in plasma samples 
and tumor biopsies harvested after administration of irinote-
can or CRLX101 at their respective MTDs. The results 
showed that, at 24 and 48 hours post-administration, plasma 
and tumor concentrations of both CRLX101 and released 
CPT were greater than four orders of magnitude and greater 
than two orders of magnitude higher than those of irinotecan 
and SN-38, respectively. These findings are correlative with 
the significantly enhanced efficacy observed with CRLX101 
compared to irinotecan in these xenograft tumor models. 
Most remarkably, the enhanced efficacy and increased tumor 
drug concentrations were correlated with increased inhibition 
of Topo 1 enzymatic activity in two of the tumor models 
(Daudi and Karpas 299) at 48 hours post-administration [22]. 
In summary, findings from the CRLX101 biodistribution 
studies provide substantive evidence that CDP nanopharma-
ceuticals can increase the efficacy of the active molecule by 
enhancing and sustaining higher localized drug concentra-
tions in target tissues. 
  Another mechanism by which CPT levels are high in 
tumors but low in the bloodstream is the physical integrity of 
CRLX101 as a nanopharmaceutical. The self-assembly of 
CRLX101 into intact nanoparticles keeps the CPT cargo 
intact, prevents premature CPT release or metabolism in 
circulation, maximizes tumor localization through the EPR 
effect, and minimizes systemic drug dissemination. To ex-
plore the extent that CRLX101 stays intact in circulation, 
multi-organ pharmacokinetics were assessed in tumor-
bearing mice in a PET/CT-study using 
64Cu-labeled 
CRLX101 [19]. Results from these experiments showed that 
there was a high tumor accumulation of CRLX101 as intact 
nanoparticles, likely by extravasation through the leaky vas-
culature in tumor tissue. This finding was further supported 
by confocal immunofluorescence microscopy that visualized 
intact nanoparticles of CRLX101 inside tumor cells 24 hours 
after administration. These are compelling results illustrating 
that the CDP technology can significantly modulate the 
pharmacokinetics, and consequently the pharmacodynamics, 
of CPT to enhance its efficacy with prolonged drug exposure 
[16], i.e. keeping CPT in its active form, increasing tumor 
drug concentrations, augmenting intracellular drug concen-
tration, and maintaining drug supply in target cells over 
longer periods of time to sustain Topo 1 and possibly HIF-
1 inhibition. 
  One of the basic goals for the design of CRLX101 is to 
improve the pharmacokinetics of CPT, increasing its circula-
tion time and improving the bioavailability of the active lac-
tone form of CPT. CRLX101 pharmacokinetics were as-
Table 1.  In Vitro Cytotoxicity of CRLX101 and CPT Against Multiple Human Cancer Cell Lines Determined by a 48 Hour MTS 
Assay 
Cell Line  IC50 CPT [μM] IC50 IT-101 [M] 
NCI-H1299 NSCLC  0.100  0.320 
HT-29 Colorectal  0.020  0.218 
A2780 Ovarian  0.007  0.039 
PANC-1 Pancreatic  0.050  0.100 
DAUDI Burkitt’s Lymphoma 0.060  0.170 
IC50: 50% inhibitory concentration. Data from T. Schluep (personal communication), references [7, 22].  
 
Table 2.  Biodistribution of CRLX101 in Nude Mice Bearing Subcutaneous, Human LS174T Colorectal Cancer Xenografts 
Level of Released, Active CPT (ng/mL or ng/g) 
CRLX101 CPT  Tissue \ Time Point 
24 hrs  48 hrs  24 hrs  48 hrs 
Plasma  72 ± 9  3 ± 3  0 ± 0  0 ± 0 
Tumor  183 ± 115  55 ± 22  1 ± 0  0 ± 0 
Liver  241 ± 132  121 ± 57  106 ± 40  108 ± 74 
Spleen  45 ± 42  13 ± 17  49 ± 15  0 ± 0 
Lung  57 ± 43  11 ± 9  8 ± 15  0 ± 0 
Heart  23 ± 21  5 ± 5  0 ± 0  14 ± 0 
Plasma and tissue collection at 24 and 48 hours after single-dose administration at respective MTDs (3 mg/kg Intraperitoneally for CPT and 24 mg/kg CPT equivalent dose intrave-
nously for CRLX101). Data are from reference [23]. 12    Current Bioactive Compounds 2011, Vol. 7, No. 1  Young et al. 
sessed in Sprague Dawley
® rats. In these studies, plasma 
samples were drawn from animals that were administered 
with either CRLX101 or CPT, and analyzed for CPT drug 
levels as either released drug or nanoparticle-bound drug. 
The mean pharmacokinetic parameters are summarized in 
Table 3. In summary, relative to the parent drug CPT, phar-
macokinetics of CRLX101 had a larger area under the curve, 
lower volume of distribution, longer terminal half-life, and 
slower systemic clearance [23]. In animals that were dosed 
with CRLX101, plasma concentrations of released CPT 
stayed well below those of nanoparticle-bound CPT by a 
factor of >30-fold at all time points, illustrating that 
CRLX101 is an effective drug depot, providing a slow, con-
tinuous drug supply while remaining in circulation and ac-
cumulating in target tissues. 
Table  3. Pharmacokinetic Parameters of CRLX101 and CPT 
in Sprague Dawley rats. Values from Reference [23]  
IT-101 (0.9 mg/kg CPT 
Equivalents)  Pharmacokinetic 
Parameter 
CPT (1.0 
mg/kg 
CPT)  Polymer 
Bound CPT 
Released 
CPT 
Cmax (μg/mL) 0.4    9.1  0.2 
Vss (mL) 1306  47.2  n/a 
CL (mL/h)  1534  3.4  n/a 
Terminal half-life (h)  1.3 17.2 n/a 
AUC (μg h/mL)  0.2  66.9  0.2 
 
  To further explore the relationship between the improved 
pharmacokinetics and enhanced pharmacodynamics of 
CRLX101, tolerability and efficacy were studied with vary-
ing dosing schedules in rodents (Table 4). Tolerability of 
CRLX101 was assessed in athymic nude mice and was ob-
served to have a strong schedule-dependency. Dosing sched-
ules with administration frequencies in excess of once per 
week were shown to be toxic, requiring significant dose re-
ductions. This is likely due to high drug accumulation from 
multi-dose regimens, given CRLX101’s long terminal half-
life and slow sustained CPT drug release kinetics. At lower 
dose frequencies, however, CRLX101 was well tolerated at 
dose levels up to 18 mg/kg. Efficacy of CRLX101 with a 
variety of dosing schedules was evaluated in nude mice bear-
ing subcutaneous human LS174T colorectal cancers and 
compared to irinotecan [24]. At all dosing schedules, 
CRLX101 was found to be superior to CPT or irinotecan 
dosed at their respective MTDs
2. Notably, weekly dosing 
was found to be highly efficacious and just as effective as 
that achieved with more frequent dosing. The weekly dosing 
schedule was found to be better tolerated, which is consistent 
with the reported released CPT pharmacokinetics and biodis-
tribution. 
                                                 
2 Irinotecan was dosed at 100 mg/kg weekly times three (qwk x 3), CPT was dosed at 3 
mg/kg every four days times five (q4d x 5), and CRLX101 was dosed daily (qd x 1) at 
18.3 mg/kg, 5/2/5/2/5 at 3.2 mg/kg, q4d x 5 at 9.7 mg/kg, and qwk x 3 at 18.3 mg/kg in 
CPT equivalents. 
Table  4.  Maximum Tolerated Dose (MTD) of CRLX101 on 
Various Dosing Schedules in Athymic Nude Mice 
[23] 
Dosing Schedule  MTD (mg/kg) 
qd x 1  24 
5/2/5/2/5 3 
q4d x 5  10 
qwk x 3  15 
MTD was defined as the dose level below which animals exhibited a mean body 
weight loss greater than 20% or greater than 10% of animal deaths in a particular 
group. 
 
  A comprehensive evaluation of CRLX101 anti-tumor 
activity has also been completed in eleven different subcuta-
neous human cancer models, including LS174T and HT29 
colorectal cancer, A2780 and SK-OV 3 ovarian cancer, 
H1299 non small-cell lung cancer, H69 small-cell lung can-
cer, Panc-1 pancreatic cancer, MDA-MB-231 breast cancer, 
along with four disseminated xenograft models, including 
TC71-luc Ewing’s sarcoma, Daudi, Karpas 299, and L540 
lymphomas [22,24]. In every case, a single treatment cycle 
of three weekly doses of CRLX101 resulted in significant 
anti-tumor activity that was superior to irinotecan or topote-
can. Most notably, complete tumor regression was observed 
in all animals bearing H1299 tumors and in the majority of 
animals with disseminated Ewing’s sarcoma, Daudi, and 
Karpas 299 lymphoma tumors. Additionally, CRLX101 was 
found to be highly effective in tumor models that respond 
poorly to treatment with irinotecan (MDA-MB-231, Panc-1, 
and HT29), suggesting CRLX101’s potential ability to over-
come drug resistance in these models. These findings pro-
vide compelling support that CDP as a nanopharmaceutical 
technology has (a) successfully overcome CPT’s formula-
tion, toxicity, and pharmacokinetic challenges, (b) main-
tained CPT in its active form resulting in potent anti-tumor 
activity, (c) increased intracellular CPT concentrations, (d) 
enhanced tumor drug localization and retention, and (e) pro-
duced a sustained therapeutic effect with superior efficacy 
over approved Topo 1 inhibitors. 
  Because CRLX101 as a nanopharmaceutical has an in-
creased therapeutic window, an important clinical implica-
tion is that it can be more easily combined with other che-
motherapeutic agents for synergistic activity. Studies were 
conducted with CRLX101 combined with highly efficacious 
chemotherapeutic agents, including cisplatin, carboplatin, 
paclitaxel, and gemcitabine. Antitumor activity of such drug 
combinations were tested in xenograft tumor mouse models, 
including human A2780 and SK-OV-3 ovarian carcinoma 
[25]. In these studies, all CRLX101 drug combinations tested 
were found to exhibit greater than additive efficacy, com-
pared to the single-agent activity observed with each of the 
individual chemotherapeutic agents. Furthermore, in the case 
of cisplatin, paclitaxel, and gemcitabine, the observed en-
hanced efficacy from combination therapy was achieved 
without additive toxicity. A key clinical implication from 
these findings is that CRLX101 can be developed as a highly 
versatile chemotherapeutic agent that has significant mono-CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical  Current Bioactive Compounds 2011, Vol. 7 No. 1    13 
therapy activity, with the potential for combination with 
multiple widely-used oncology agents. 
3. CLINICAL PHASE 1 STUDY WITH CRLX101 
  Data from the preclinical studies of CRLX101 have con-
firmed that the CDP nanopharmaceutical technology has 
successfully conferred superior pharmacokinetics, improved 
tolerability, enhanced pharmacodynamics, and increased 
efficacy to CPT. Considering the original promise of CPT as 
an anti-tumor agent and the favorable pharmaceutical profile 
of its nanopharmaceutical design and configuration, 
CRLX101 is considered a promising oncology agent and 
clinical development was initiated. A Phase 1/2a study is 
currently underway and a Phase 2 study is being planned. 
4. PERSPECTIVE 
  The application of polymeric nanoparticles for address-
ing formulation and pharmacokinetic challenges has long 
been a hot topic in drug delivery research and development. 
Advances in polymer chemistry and a better understanding 
of tumor microenvironment biology have supported the pro-
gress of nanopharmaceuticals as a new class of therapeutic 
agents. While other nanometer-scale drug carrier technolo-
gies and approaches have demonstrated an ability to over-
come some of the formulation and pharmacokinetic hurdles, 
development of CRLX101 as a first-in-class nanopharma-
ceutical has established that cyclodextrin polymeric nanopar-
ticle (CDP) technology is a highly versatile nanopharmaceu-
tical platform technology that confers significant biological 
advantages to active pharmaceutical ingredients, including 
target-tissue localization, enhanced cellular uptake, and slow 
drug release kinetics resulting in sustained therapeutic drug 
concentrations in target cells. Together, these biological 
properties have a strong potential to translate therapy into 
significant impact on clinical outcome.  
  Cerulean Pharma Inc. is advancing CRLX101 in Phase 
1/2a clinical development. One of the key objectives of the 
study will be to investigate the activity of CRLX101 in a 
variety of tumor types. Another objective of the study will be 
to collect more long-term safety data in patients who are 
responding to CRLX101 and exhibiting stable disease. These 
findings will be critical for establishing CRLX101’s poten-
tial as a new oncology agent and for developing human 
proof-of-concept data for CDP-based nanopharmaceuticals. 
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